arrow
N

Nikolaus Jilg

Harvard University
H指数:25
被引数:3,636

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial

急性新型冠状病毒肺炎后结局,包括参与者报告的长期COVID: ACTIV-2试验中amubarvimab/romlusevimab与安慰剂的比较

2024-09-010
OAAI
Severe Acute Respiratory Syndrome Coronavirus 2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With Coronavirus Disease 2019

新型冠状病毒血浆抗体和核衣壳抗原状态可预测冠状病毒病门诊患者的预后2019

2024-07-171
PRE
SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir

SARS-CoV-2 RNA和核衣壳抗原是与严重疾病结局相关的血液生物标志物,对Remdesivir的反应有所改善

2024-04-243
OA
Viral and host mediators of non-suppressible HIV-1 viremia

不可抑制的HIV-1病毒血症的病毒和宿主介质

2023-11-1313
OAAI
Long COVID After Bamlanivimab Treatment
2023-08-312
OA
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial
2023-06-059
PRE
Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case
2023-05-271
OA
SARS-CoV-2 viral load is associated with increased disease severity and mortality
2020-10-30636
OAAI